Entering text into the input field will update the search result below

Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q4 2019 Results - Earnings Call Transcript

Mar. 03, 2020 12:13 AM ETFate Therapeutics, Inc. (FATE)
SA Transcripts profile picture
SA Transcripts

Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2019 Earnings Conference Call March 2, 2020 5:00 PM ET

Company Participants

Scott Wolchko - President and Chief Executive Officer

Daniel Shoemaker - Chief Scientific Officer

Wayne Chu - Senior Vice President of Clinical Development

Conference Call Participants

Mara Goldstein - Mizuho Securities USA LLC

Alethia Young - Cantor Fitzgerald & Co.

James Birchenough - Wells Fargo Securities, LLC

Edward Tenthoff - Piper Sandler & Co.

Benjamin Burnett - Stifel, Nicolaus & Company, Inc.

Kelsey Goodwin - Guggenheim Securities, LLC

Biren Amin - Jefferies LLC

Matthew Biegler - Oppenheimer & Co. Inc.

Amanda Murphy - BTIG, LLC


Welcome to the Fate Therapeutics' Fourth Quarter 2019 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Fate's website at fatetherapeutics.com. As a reminder, today's call is being recorded.

I would now like to introduce Scott Wolchko, President and CEO of Fate Therapeutics.

Scott Wolchko

Thank you. Good afternoon and thanks, everyone, for joining us for the Fate Therapeutics' fourth quarter 2019 financial results call. Shortly after 4:00 PM Eastern Time today, we issued a press release with these results which can be found on the Investors and Media section of our website under Press Releases. In addition, our Form 10-K for the year ended December 31, 2019, was filed shortly thereafter and can be found on the Investors and Media section of our website under Financial Information.

Before we begin, I would like to remind everyone that, except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.

These statements involve risks and

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.